The global neuroendocrine carcinoma treatment market is estimated to be worth USD 1,976 million in 2024. The CAGR for neuroendocrine carcinoma treatment is forecast to be 8.1% between 2024 and 2034. According to estimates, the market size is likely to reach USD 4,305.7 million by 2034.
A growing number of biological markers and well-established diagnostic methods have improved detection rates of neuroendocrine cancers. Governments in developed and developing nations offer awareness programs in an attempt to promote early cancer diagnosis, which can lead to better treatment outcomes.
Request A Sample Copy of This Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-1278
Researchers are trying to create intelligent chemotherapy that targets tumor cells only, sparing healthy cells. As a result of this strategy, adverse effects can be reduced, and the therapeutic results can be enhanced. Systemic medicines, such as chemotherapy and targeted therapy, are used to treat neuroendocrine tumors that have spread or progressed. Cancer cells that divide rapidly are killed using chemotherapy medications, such as etoposide and cisplatin. Somatostatin analogs and tyrosine kinase inhibitors, for example, target particular pathways responsible for tumor development and spread.
Research and medical professionals are always working on new and creative approaches to treating the disease. In the Dana-Farber Brigham Cancer Center’s Neuroendocrine and Carcinoid Tumors Program, cutting-edge experiments are being conducted to identify the molecular pathways that cause neuroendocrine tumors to develop. New targets will be identified, and new, more effective treatment approaches will be accelerated through this research.
Emerging molecular and clinical findings are challenging the established paradigm for treating neuroendocrine carcinomas. The use of medicines that do not require tumors as a source of resistance to treatment is being investigated. RET and NTRK gene fusions, as well as BRAF or KRAS inhibitors, are all studies focused on specific genetic changes, including microsatellite instability, high tumor mutational burden, and microsatellite instability.
“Cure for neuroendocrine carcinomas and the development of new cancer vaccines and drugs with targeted therapies are expected to see increased growth in the near future. The combination of increased clinical studies and the launch of new products will continue to drive the industry forward.” – Says an analyst at FMI.
Key Takeaways from the Neuroendocrine Carcinoma Treatment Market:
- In 2023, gastric neuroendocrine tumors accounted for 46.8% share of global revenue.
- In the United States, the market is expected to expand at a CAGR of 8.3% through 2034.
- Market growth in France is expected to take place at a CAGR of 7.5% during the forecast period.
- A CAGR of 9% is expected to be observed between 2024 and 2034 for the market in India.
- Based on treatment type, somatostatin analogs held 61.2% of the market in 2023.
Get Customization on This Report: https://www.futuremarketinsights.com/customization-available/rep-gb-1278
Competitive Landscape:
Market players work closely with regulatory agencies to ensure safety and efficacy standards are met and to expedite approval processes. Neuroendocrine carcinoma treatments are often researched and developed at great expense by businesses. For clinical trials to be successful, preclinical research is also fundamental to the identification and development of potential therapeutic targets. New medicines are being evaluated in clinical trials to determine their efficacy and safety. Patients and healthcare professionals often participate in clinical studies to assess the efficacy of their treatments.
Recent Development:
- In September 2023, Novartis targeted Lutathera for first-line use in neuroendocrine tumors after a successful trial. The United States Food and Drug Administration (FDA) approved Lutathera in 2018 for the treatment of GEP-NETs with somatostatin receptor positivity. Novartis pointed to the positive phase 3 NETTER-2 trial readout to highlight Lutathera’s clinically meaningful progression-free survival benefit.
- In April 2024, Pfizer and Genmab announced the United States FDA had approved the supplemental Biologics License Application (sBLA) granting full approval for TIVDAK (tisotumab vedotin-tftv) as a therapy for patients with recurrent or metastatic cervical cancer.
Company Profile:
- Pfizer Inc.
- Novartis AG
- Chiasma Inc.
- Hutchison China MediTech Ltd
- Abbvie Inc.
- Valeant Pharmaceuticals International Inc.
- Jubilant Life Sciences Ltd.
- Teva Pharmaceutical Industries Ltd
- F. Hoffmann-La Roche Ltd
- Advanced Accelerator Applications
- Mateon Therapeutics, Inc.
A Full Report Analysis: https://www.futuremarketinsights.com/checkout/1278
Key Segments of Market Report:
By Disease Indication Type:
Based on disease indication type, the industry is classified into gastric neuroendocrine tumors, lung neuroendocrine tumors, pancreatic neuroendocrine tumors, and appendicular neuroendocrine tumors.
By Treatment Type:
Based on the treatment type, the industry is categorized into somatostatin analogs, targeted therapy (tyrosine kinase inhibitors, mTOR inhibitors), and chemotherapy (antimetabolites, alkylating agents, natural products).
By End User:
In terms of end users, the industry is classified into hospitals, clinics, oncology centers, and ambulatory surgery centers.
By Region:
Key countries of North America, Latin America, East Asia, South Asia, Western Europe, Eastern Europe, and the Middle East and Africa are covered in the regional analysis.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
